Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Europe seen weaker as more rate hikes loom

Mon, 12th Dec 2022 07:44

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPE SEEN WEAKER AS MORE RATE HIKES LOOM (0740 GMT)

European shares are set to kick off a macro-packed week on the back foot, tracking Friday's late losses on Wall Street and weakness earlier in Asia, where spreading COVID cases in China added to the downbeat mood.

EuroSTOXX50, DAX and FTSE futures fell between 0.3 and 0.5%, while the MSCI's broadest index of Asia-Pacific shares outside Japan fell 1.3%. U.S. futures meanwhile pointed to softer start on Wall Street.

On the European corporate news front, shares in London Stock Exchange will be in focus after Microsoft agreed to take 4% in the UK exchange operator as part of deal to migrate the bourse operator's data platform into the cloud.

Eyes also on Sanofi after the French health group dropped plans to bid for Horizon Therapeutics, while in Italy, Tod's founder ditched plans to delist the shoemaker after a buy-out that didn't meet a key threshold.

Still in M&A, Superdry is another one to watch after the Sunday Times reported CEO and founder Julian Dunkerton has held talks with private equity firms about a possible buyout.

HUNKERING DOWN (0659 GMT)

Just as China faces a testing time over its dramatic COVID-19 policy pivot, financial markets are on full alert ahead of interest rate decisions coming out this week from the world's top central banks.

Initial market enthusiasm over China's easing of its stringent "zero-COVID" measures has now switched to worries over a wave of infections likely disrupting the economy.

European stock markets are set for a weaker start on Monday, dragged by declines in Asian stocks, with the spotlight on a series of central bank meetings even as expectations rise that euro zone inflation is peaking.

The European Central Bank is set to take its deposit rate up by 50 basis points to 2%, despite the euro zone economy almost certainly being in recession, as it battles inflation running at five times its target, a Reuters poll found.

It's a Super Thursday this week, with the ECB, Bank of England, and the Swiss and Norwegian central banks also expected to jack up borrowing costs. What markets are keen to find out is whether they are nearly done.

On Sunday, U.S. Treasury Secretary Janet Yellen forecast a substantial reduction in U.S. inflation in 2023, barring an unexpected shock.

Whether inflation is responding to the most aggressive Fed hiking cycle since the 1980s will be evident in this week's U.S. consumer price index report. On the corporate front, while French health group Sanofi announced it had dropped its bid for biotech company Horizon Therapeutics, the Wall Street Journal reported that Amgen is in advanced talks to buy Horizon.

Meanwhile, a consolidation is shaping up in the food delivery market as Turkish delivery company Getir bought German rival Gorillas in a deal worth $1.2 billion, merging two of the remaining companies in Europe promising groceries in minutes.

Key developments that could influence markets on Monday:

Economic data: UK October GDP and industrial output

More News
12 Dec 2022 17:26

European shares slip on fears over rising China COVID cases, await rate decisions

STOXX 600 down 0.5%

*

Read more
12 Dec 2022 11:25

Three-way split coming at BoE

STOXX down 0.4%, volatility hits 1-mo high

*

Read more
12 Dec 2022 10:48

What to prefer in 2023: Europe or America?

STOXX down 0.4%, volatility hits 1-mo high

*

Read more
12 Dec 2022 06:59

Hunkering down

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

Read more
7 Dec 2022 17:43

European shares fall for fourth day on growth worries

STOXX 600 falls for the fourth straight day

*

Read more
7 Dec 2022 12:16

GSK, Sanofi shares soar as Zantac litigation fears abate

Thousands of Zantac lawsuits dismissed on Tuesday

*

Read more
7 Dec 2022 11:43

Winter is coming... and so are earnings downgrades

STOXX 600 falls 0.5%

*

Read more
7 Dec 2022 11:22

Being bearish but also bullish on Europe Inc

STOXX 600 down 0.5%

*

Read more
7 Dec 2022 09:24

Forza Italia in early Europe

STOXX 600 down 0.2%

*

Read more
7 Dec 2022 08:09

Sanofi shares rally as company avoids U.S. lawsuits over Zantac

PARIS, Dec 7 (Reuters) - Sanofi shares rose by around 8% in early Paris stockmarket trading on Wednesday after the company avoided thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.

Read more
6 Dec 2022 23:12

GSK, Pfizer, Sanofi fend off thousands of U.S. lawsuits over alleged Zantac cancer link

Dec 6 (Reuters) - Drugmakers GSK Plc, Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday were spared thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.

Read more
6 Dec 2022 19:51

GSK, Pfizer, Sanofi escape U.S. federal litigation over Zantac

Dec 6 (Reuters) - Drugmakers GSK Plc, Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday defeated thousands of lawsuits in U.S. federal court claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.

Read more
2 Dec 2022 17:15

Europe's STOXX 600 slips, but marks seventh week of gains

Sanofi slips amid Horizon deal talks

*

Read more
2 Dec 2022 11:15

Sanofi says any offer for Horizon Therapeutics, if made, will be in cash

PARIS, Dec 2 (Reuters) - French drugmaker Sanofi said on Friday that if it decides to bid for biotech company Horizon Therapeutics Plc, it would do so in cash.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.